---
schema_version: "secwatch.filing_event.v1"
accession: "0001759425-26-000036"
form_type: "8-K"
ticker: "MIRM"
cik: "0001759425"
company_name: "Mirum Pharmaceuticals, Inc."
filed_at: "2026-05-06T23:59:59+00:00"
generated_at: "2026-05-14T22:49:54.477266+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Mirum Q1 net sales $159.9M, raises FY guidance to $660-680M; volixibat & brelovitug meet primary endpoints

## Summary
- Q1 2026 net product sales $159.9M, up 43% YoY; LIVMARLI $113.8M (+55%), Bile Acid Medicines $46.1M (+20%).
- Full-year 2026 net product sales guidance raised to $660-680M from prior range.
- Volixibat VISTAS Phase 2b in PSC met primary endpoint; NDA submission expected H2 2026.
- Brelovitug AZURE-1 Phase 2b in HDV met primary endpoint; Phase 3 enrollment complete, topline H2 2026.
- In-licensed zilurgisertib for FOP from Incyte for $16M upfront; FDA Priority Review, PDUFA Sept 26, 2026.

## SEC filing metadata
- accession: 0001759425-26-000036
- form_type: 8-K
- ticker: MIRM
- cik: 0001759425
- company_name: Mirum Pharmaceuticals, Inc.
- filed_at: 2026-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759425/000175942526000036/0001759425-26-000036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759425/000175942526000036/mirm-20260506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001759425-26-000036
- JSON: https://secwatch.observer/filing/0001759425-26-000036.json
- Plain text: https://secwatch.observer/filing/0001759425-26-000036.txt

## Source-grounded claims
- claim_id: a0ccd53701ab7846bcac39a5b004b0e759410a59
  claim: Mirum Pharmaceuticals, Inc. reported the quarter ended March 31, 2026 results: revenue $159.9 million. Guidance raised.
  evidence_excerpt: in such filing. --- EX-99.1 (EX-99.1) --- Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update – Q1 2026 net product sales of $159.9 million – 2026 net product sales guidance increased to $660 to $680 million – Volixibat VISTAS Phase 2b study met primary endpoint – Brelovitug Phase 2b portion of AZURE-1 study met
  evidence_url: https://www.sec.gov/Archives/edgar/data/1759425/000175942526000036/0001759425-26-000036-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.